Updated
Updated · The New York Times · Jul 10
Lupin Recalls 2 Million Eye Drop Bottles Over Contamination Risk
Updated
Updated · The New York Times · Jul 10

Lupin Recalls 2 Million Eye Drop Bottles Over Contamination Risk

3 articles · Updated · The New York Times · Jul 10

Summary

  • More than 2 million bottles of Lupin’s prednisolone acetate ophthalmic suspension were voluntarily recalled after a foreign substance was found that could compromise the drug’s safety.
  • The FDA said the risk of severe injury appears remote, and no injuries had been reported as of Friday from the India-made steroid drops, which are used to reduce inflammation after surgery or treat irritation.
  • Patients were told to check lot numbers against the FDA recall notice, discard affected bottles and contact an eye doctor for a replacement rather than abruptly stopping steroid treatment, which can trigger rebound inflammation.
  • The recall adds to a string of eye-product safety problems, including a 2023 outbreak tied to four deaths, as specialists warn that limited oversight of foreign manufacturers and recent FDA inspection cuts could worsen such risks.

Insights

With millions of Indian eye drops recalled, can the understaffed FDA still guarantee the safety of America's imported medicines?
India is the world's pharmacy, but after another major recall, are its cheap generic drugs a dangerous bargain for patients?
Are razor-thin profits forcing generic drugmakers to sacrifice safety, leading to a surge in dangerous product recalls?